The Small Interfering RNA (siRNA) Therapeutics Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 4.89 Bn by the year 2031 at a 15.0% CAGR during the forecast period for 2024-2031.
Small interfering RNA (siRNA) therapeutics describe a group of medicinal interventions that target disease-causing genes using small, engineered RNA molecules. Market expansion for siRNA treatments is driven by rising demand for precision medicine, new delivery platforms, and our increasing molecular understanding of disease causes. In addition, the increasing occurrence of chronic diseases presents numerous opportunities for creating and commercializing treatments based on small interfering RNAs.
Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in research initiatives from governments, private organizations, and pharmaceutical companies. In addition, the market of siRNA therapies is rising due to rising patient consciousness and the need for more precise, individualized treatments.
However, the market growth is hampered by the strict regulatory criteria of small interfering RNA (siRNA) therapeutics, therapies that can be expensive, and lengthy approval procedures for novel therapies, which are compounded by technical problems and obstacles to market expansion. In addition, because of the growing consensus among regulatory bodies regarding the therapeutic value of cancer, promising medications are being expedited through the review and approval processes, driving market growth. Furthermore, factors driving market expansion include an uptick in cancer HIV cases globally and a surge in research and development efforts related to creating these medications. Small interfering RNA therapeutics are in high demand because tumours, hereditary diseases, and viruses are on the rise worldwide.
Competitive Landscape
Some Major Key Players In The Small Interfering RNA (siRNA) Therapeutics Market:
- Alnylam
- Silence Therapeutics
- Silenseed Ltd
- Sylentis, S.A.
- Sanofi Genzyme
- Quark Pharmaceuticals
- Dicerna Pharmaceuticals
- Arrowhead Pharmaceuticals
- Novartis
- Novo Nordisk
- Johnson & Johnson company
- GSK
- Aro Biotherapeutics
- Other Market Players
Market Segmentation:
The small interfering RNA (siRNA) therapeutics market is segmented based on delivery, indication and Route of Administration (RoA). The Delivery segment includes Lipid Nanoparticles (LNPs), Conjugates. According to the Indication segment, the market includes Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others. By RoA, the segmentation comprises Intravenous (IV) and Subcutaneous.
Based On The Delivery, The LNPs delivery system in Small Interfering RNA (siRNA) Therapeutics Market Segment Is Accounted As A Major Contributor To The Small Interfering RNA (siRNA) Market.
The lipid nanoparticle (LNPs) in small interfering RNA (siRNA) therapeutics market is expected to hold a major global market share owing to its capacity to improve the stability and transport of siRNA molecules.
In The Region, The North American Small Interfering RNA (siRNA) Therapeutics Market Holds A Significant Revenue Share.
The North American small interfering RNA (siRNA) therapeutics market is expected to report the biggest market share in revenue in the near future. It can be attributed to the heavy financial backing for pharmaceutical and biotech research, a well-developed healthcare system, and the headquarters of prominent pharmaceutical corporations. There is a high incidence of chronic diseases, helpful legislative frameworks, and substantial public financing for small interfering RNA treatment methods, which is growing the region's growth. In addition, Asia Pacific is estimated to grow very fast in the global small interfering RNA (siRNA) therapeutics market because of the big population and increasing requirement of high-quality healthcare in the region, and the increasing awareness of advanced treatment alternatives is driving the fast growth of the siRNA therapeutics industry in the Asia Pacific region.
Recent Developments:
- In April 2024, Wave Life Sciences reported ongoing progress in their partnership with GSK and achieved notable breakthroughs in siRNA and RNA editing. Wave partnered with GSK and identified its initial two programs for further development after successfully validating their targets. These applications utilized Wave's advanced GalNAc-siRNA format, which is the next generation in the field of hepatology.
Small Interfering RNA (siRNA) Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.6 Bn |
|
Revenue Forecast In 2031 |
USD 4.89 Bn |
|
Growth Rate CAGR |
CAGR of 15.0% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Delivery, Indication and Route of Administration (RoA) |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Alnylam, Silence Therapeutics, Silenseed Ltd, Sylentis, S.A., Sanofi Genzyme, Quark Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Novo Nordisk, Johnson & Johnson company, GSK, Aro Biotherapeutics and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
